Evidence map›Paper›PMID 41045934›Full record

Trial reportCell reports. Medicine2025

4-1BB

Junha Cha, Chang Gon Kim, Nam Suk Sim, Gamin Kim, Wonrak Son, Dahee Kim, Yurim Jung, Hyun Jun Hong, Hae Been Lee, Jaehyung Kim and 11 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Junha ChaDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Chang Gon KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Nam Suk SimDepartment of Otorhinolaryngology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Gamin KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Wonrak SonDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Dahee KimDepartment of Otorhinolaryngology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Yurim JungDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea.
Hyun Jun HongDepartment of Otorhinolaryngology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Hae Been LeeDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea.
Jaehyung KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Jinna KimDepartment of Radiology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Sun Och YoonDepartment of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul 03722, Republic of Korea.
Seokhyeong GoDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Jeongah KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Euijung SeongDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea.
Seungbyn BaekDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea.
Kyung Hwan KimDepartment of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Min Hee HongDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. Electronic address: minhee_hong@yuhs.ac.
Yoon Woo KohDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. Electronic address: ywkohent@yuhs.ac.
Insuk LeeDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea; POSTECH Biotech Center, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea. Electronic address: insuklee@yonsei.ac.kr.
Hye Ryun KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. Electronic address: nobelg@yuhs.ac.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predictors of immune checkpoint inhibitor response in cancer remain elusive. From a previous phase 2 neoadjuvant immunotherapy window-of-opportunity study, we present the single-cell RNA and T cell receptor (TCR) sequencing analysis of 57 pre- and post-treatment tumor biopsies from head and neck cancer patients treated with durvalumab (anti-PD-L1) alone or with tremelimumab (anti-CTLA-4), identifying key cellular and molecular predictors of immune checkpoint inhibitor (ICI) response. Malignant cells and neutrophil senescence promote ICI response. While CXCL13

Indexed as

B7-H1 AntigenCTLA-4 AntigenDrug Resistance, NeoplasmImmune Checkpoint InhibitorsT-Lymphocytes, RegulatoryTumor Necrosis Factor Receptor Superfamily, Member 9Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedFemaleHumansImmunotherapyMaleAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humandurvalumabImmune Checkpoint InhibitorsTNFRSF9 protein, humantremelimumabTumor Necrosis Factor Receptor Superfamily, Member 9dual ICBdurvalumabhead and neck squamous cell carcinomaimmune checkpoint inhibitorimmunotherapyprogenitor exhausted Tsingle-cell RNAsingle-cell TCRtremelimumab

Identifiers

PMID41045934
PMCPMC12629806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.